Treatment of malaria with liposomes containing 8-aminoquinoline derivatives and glycoconjugates
US4416872A · kind A · utility
25Cited by
2References
64Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 17, 1982 |
| Grant date | Nov 22, 1983 |
| Priority date | — |
| Expiry date | Mar 17, 2002 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel treatment has been discovered for interrupting the life cycle of malaria parasite during its development in the liver of the vertebrate host. The subject invention involves a method of chemotherapy against sporozoite-induced malaria by administering an 8-aminoquinoline drug, such as primaquine, encapsulated within liposomes containing glycoconjugates, to a vertebrate host which has been infected with sporozoites of the parasites. Preferred species of glycoconjugates have a terminal glucose or galactose moiety, such as present in glycosyl ceramide, galactosyl ceramide, lactosyl ceramide, or in glycoproteins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.